Cargando…

In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes

Aging is the main risk factor for cardiovascular disease (CVD). As the world's population ages rapidly and CVD rates rise, there is a growing need for physiologically relevant models of aging hearts to better understand cardiac aging. Translational research relies heavily on young animal models...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozcebe, S. Gulberk, Zorlutuna, Pinar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652343/
https://www.ncbi.nlm.nih.gov/pubmed/37803909
http://dx.doi.org/10.1111/acel.13966
_version_ 1785136188378578944
author Ozcebe, S. Gulberk
Zorlutuna, Pinar
author_facet Ozcebe, S. Gulberk
Zorlutuna, Pinar
author_sort Ozcebe, S. Gulberk
collection PubMed
description Aging is the main risk factor for cardiovascular disease (CVD). As the world's population ages rapidly and CVD rates rise, there is a growing need for physiologically relevant models of aging hearts to better understand cardiac aging. Translational research relies heavily on young animal models; however, these models correspond to early ages in human life, therefore cannot fully capture the pathophysiology of age‐related CVD. Here, we first investigated the transcriptomic and proteomic changes that occur with human cardiac aging. We then chronologically aged human induced pluripotent stem cell‐derived cardiomyocytes (iCMs) and showed that 14‐month‐old iCMs exhibited a similar aging profile to the human CMs and recapitulated age‐related disease hallmarks. Using aged iCMs, we studied the effect of cell age on the young extracellular matrix (ECM) therapy, an emerging approach for myocardial infarction (MI) treatment and prevention. Young ECM decreased oxidative stress, improved survival, and post‐MI beating in aged iCMs. In the absence of stress, young ECM improved beating and reversed aging‐associated expressions in 3‐month‐old iCMs while causing the opposite effect on 14‐month‐old iCMs. The same young ECM treatment surprisingly increased SASP and impaired beating in advanced aged iCMs. Overall, we showed that young ECM therapy had a positive effect on post‐MI recovery; however, cell age was determinant in the treatment outcomes without any stress conditions. Therefore, “one‐size‐fits‐all” approaches to ECM treatments fail, and cardiac tissue engineered models with age‐matched human iCMs are valuable in translational basic research for determining the appropriate treatment, particularly for the elderly.
format Online
Article
Text
id pubmed-10652343
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106523432023-10-06 In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes Ozcebe, S. Gulberk Zorlutuna, Pinar Aging Cell Research Articles Aging is the main risk factor for cardiovascular disease (CVD). As the world's population ages rapidly and CVD rates rise, there is a growing need for physiologically relevant models of aging hearts to better understand cardiac aging. Translational research relies heavily on young animal models; however, these models correspond to early ages in human life, therefore cannot fully capture the pathophysiology of age‐related CVD. Here, we first investigated the transcriptomic and proteomic changes that occur with human cardiac aging. We then chronologically aged human induced pluripotent stem cell‐derived cardiomyocytes (iCMs) and showed that 14‐month‐old iCMs exhibited a similar aging profile to the human CMs and recapitulated age‐related disease hallmarks. Using aged iCMs, we studied the effect of cell age on the young extracellular matrix (ECM) therapy, an emerging approach for myocardial infarction (MI) treatment and prevention. Young ECM decreased oxidative stress, improved survival, and post‐MI beating in aged iCMs. In the absence of stress, young ECM improved beating and reversed aging‐associated expressions in 3‐month‐old iCMs while causing the opposite effect on 14‐month‐old iCMs. The same young ECM treatment surprisingly increased SASP and impaired beating in advanced aged iCMs. Overall, we showed that young ECM therapy had a positive effect on post‐MI recovery; however, cell age was determinant in the treatment outcomes without any stress conditions. Therefore, “one‐size‐fits‐all” approaches to ECM treatments fail, and cardiac tissue engineered models with age‐matched human iCMs are valuable in translational basic research for determining the appropriate treatment, particularly for the elderly. John Wiley and Sons Inc. 2023-10-06 /pmc/articles/PMC10652343/ /pubmed/37803909 http://dx.doi.org/10.1111/acel.13966 Text en © 2023 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Ozcebe, S. Gulberk
Zorlutuna, Pinar
In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes
title In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes
title_full In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes
title_fullStr In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes
title_full_unstemmed In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes
title_short In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes
title_sort in need of age‐appropriate cardiac models: impact of cell age on extracellular matrix therapy outcomes
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652343/
https://www.ncbi.nlm.nih.gov/pubmed/37803909
http://dx.doi.org/10.1111/acel.13966
work_keys_str_mv AT ozcebesgulberk inneedofageappropriatecardiacmodelsimpactofcellageonextracellularmatrixtherapyoutcomes
AT zorlutunapinar inneedofageappropriatecardiacmodelsimpactofcellageonextracellularmatrixtherapyoutcomes